Mateo Hevia

Urólogo, PhD, FEBU. Cáncer de próstata, cirugía oncológica (laparoscopia/robot) y trasplante renal @HUCA_Asturias. Profesor asociado Urología @uniovi_info

[Jorge García @Jorge_GarciaRod]

Tras meses de trabajo, presentamos la versión de evaluación de la 2.ª edición del Protocolo en #CáncerDePróstata
Basada en la evidencia científica actual y en el trabajo multidisciplinar

La edición definitiva estará disponible en septiembre.

@HUCA_Asturias @FINBAsturias

[Keith Siau @drkeithsiau]

An iPhone compatible endoscope with a diameter of 5.2mm and a 3.2mm working channel

[david andina @daandina]

Raúl Solís se “levantaba” al mes un 2650€ por un trabajo al 50% en el grupo municipal de Podemos.

Si hubiese trabajado al 100% se “levantaría” 5285€ al mes.

Si trabajase 55-60h a la semana (eso significa “con guardias”) se “levantaría” 8.000€ al mes.

El titular de redacción anti-médica es despreciable. Raúl Solís también.

[Diego Barreiro @DBarreiro4]

El FIN de la recaída bioquímica.
El PET con Cobre detecta más del doble de lesiones que el PET con Galio en la recaída post prostatectomia.
En lugar de hablar de recaída bioquímica podremos detectar el sitio de recurrencia y darle al paciente una nueva oportunidad de rescate.

[JAMA @JAMA_current]

Microultrasonography-guided biopsy was noninferior to MRI-guided biopsy for detection of clinically significant #ProstateCancer, supporting its use as an alternative imaging modality.

🎥 Watch the video and read the full study: https://t.co/2NTBpSvpeD

[MUSC Urologic Oncology Program @MUSC_UroOnc]

🚨🚨 Novel Technique for Stent Placement During Ureteroureterostomy

@MatveyTsivian describes a resource-efficient intraoperative stenting technique that avoids cystoscopy and patient repositioning, with no observed stent malposition.

Check it out! 🔗 https://t.co/sF9okbhlpH

@JayChavaliMD @benvstone @EMW2000 @LuisMedinaMD @JL_Drerup @Emily_Neckonoff

[Dr Rishabh Jain @DrRishabhOnco]

🚨 Prostate cancer care has changed fast. Here’s the 2025 snapshot.

The new Lancet Seminar lays out how prostate cancer management has transformed across the disease spectrum 🌍🧬

🔍 Early disease
Active surveillance is the default for low-risk tumors, avoiding overtreatment while maintaining excellent outcomes. MRI-first pathways improve detection of clinically significant cancer.

⚖️ Localized to high-risk
Surgery and modern radiotherapy offer equivalent cancer control. Hypofractionation and SBRT shorten treatment without compromising efficacy. High-risk disease needs multimodality care.

🚀 Metastatic hormone-sensitive
ADT alone is no longer enough. Doublet or triplet therapy with ARPIs ± docetaxel is now standard, with prostate RT benefiting low-volume disease.

🎯 mCRPC era
Treatment is biology-driven: PARP inhibitors for HRR alterations, Lu-177 PSMA radioligand therapy after ARPI and taxanes, cabazitaxel preferred over ARPI sequencing.

🧠 Big takeaway
Sequencing, patient selection, toxicity, and shared decision-making matter as much as drug choice.

📖 Valérie Fonteyne et al. Lancet 2025
A must-read, practice-defining review for every GU oncologist 🔖

#OncoTwitter #MedTwitter #ProstateCancer #GUOncology @TheLancet @myESMO @OncoAlert @ASCO

[Urologeman (Nariman Gadzhiev) @Urologeman]

📱 Uroflowmetry in your pocket? Sounds like fiction — but it’s real.

Smartphone + AI delivers Qmax comparable to standard uroflowmetry with gold-standard accuracy:
✔️ 96.8% agreement
✔️ 0.04 ml/s mean error

No cables. No clinic stress.
This is how home urology monitoring begins.

🔗 https://t.co/4HfoF3A77f

@DocGauhar @endouro 👏👏👏🙏

[Jorge García @Jorge_GarciaRod]

Gracias @actasurologicas por publicar nuestra serie @HUCA_Asturias
🔵 ⬇️90%de PSA, PSA< 0,2 ng/ml y PSAultrabajo (< 0,02 ng/ml) a 3 y 6m de 63 y 65, 34 y 65, 71 y 53%
🔵 91,6% libres de progresiónRx 24m conPSMA como prueba inicial.
🔵 Mantiene FACT-P
Autoevaluamos para mejorar

[Dr_KevinZorn @Dr_KevinZorn]

New #BPH tip/trick with no cost/learning curve. Keep it simple surgeon #KISS principles @#siu2025
👉 COLD 🥶 water (1-4 C) for catheter balloon inflation provides the intra-prostate tissue cooling. We call it PRICE (prostate rapid ice compression endo-hemostasis). @SIU_urology

[Jorge García @Jorge_GarciaRod]

Publicamos el análisis de datos de práctica clínica real en pacientes con #cáncerdepróstata metastásico hormonosensible @HUCA_Asturias
🔵 Respuesta a tratamiento
🔵 Progresión
🔵 Calidad de vida
Identificar áreas de mejora
Gracias a @actasurologicas
https://t.co/qmrEAz3DaV

[Prostate Cancer and Prostatic Diseases @pcan_journal]

1️⃣ 📊 PSA density + mpMRI: New study finds lesion location matters! For PI-RADS 3:
🔹 PZ lesions → risk rises at PSAd ≥0.05
🔹 TZ lesions → risk rises at PSAd ≥0.13
For PI-RADS ≥4 ➡️ risk stays high regardless.
🩺 Read more: [https://t.co/MAVA2QzTHb]

[Consejería de Salud @astursalud]

𝙄𝙄 𝙅𝙤𝙧𝙣𝙖𝙙𝙖 𝙥𝙖𝙧𝙖 𝙥𝙖𝙘𝙞𝙚𝙣𝙩𝙚𝙨 𝙘𝙤𝙣 𝙘á𝙣𝙘𝙚𝙧 𝙙𝙚 𝙥𝙧ó𝙨𝙩𝙖𝙩𝙖 𝙮 𝙛𝙖𝙢𝙞𝙡𝙞𝙖𝙧𝙚𝙨
➡️Talleres para aprender qué ejercicios son adecuados
📌Zona del Atrio @HUCA_Asturias
📆 19 de junio ⏰16:00 horas

[Felipe Couñago PhD @fcounago]

🔥⚡️🚀Adjuvant RT after cystectomy in high-risk bladder cancer:
•25–30% LRR despite chemo
•Safe (<5% G3–4 toxicity, 3 RCTs)
•RT ↓ LRR = worthy goal

Presented by Dr. @VedangMurthy Murthy at #ESTRO2025
#BladderCancer #Radiotherapy #OncoTwitter

[Igor Sorokin @DrIgorSorokin]

I learned some cool stuff at the AUA other than craps 🎲. Here are some things I found interesting #AUA25 🎰

1. Vesical mucosa grafts instead of buccal for ureteroplasty. Italian group with success in all 14 patients. With some muscle backing behind it seems ideal.

[Juan Gómez Rivas @JGomezRivas]

External validation of nomograms for predicting lymph node invasion (LNI) in prostate cancer patients with negative PSMA PET-CT. What did we find? The Briganti 2023 nomogram is the most accurate! 📊✅

🔍 Why does it matter?
Extended pelvic lymph node dissection (ePLND) is the gold standard for staging but comes with risks. With PSMA PET-CT revolutionizing imaging, we need better predictive tools to avoid unnecessary procedures.

📌 Key Findings:
•Among 282 patients, 13% had LNI despite negative PSMA PET-CT.
•The Briganti 2023 nomogram outperformed others (C-index: 77% vs. MSKCC 64%, Briganti 2017 69%, Amsterdam-Brisbane-Sydney 64%).
•Using a 5% risk cutoff would spare 47% of ePLND procedures while missing only 3.8% of LNI cases! 🚫🔬

⚖️ Clinical Impact:
•Improves decision-making: More precise risk stratification means fewer unnecessary surgeries.
•Saves patients from complications: ePLND has side effects; avoiding it when possible is crucial.
•Guides personalized treatment: Selecting the right patients for ePLND enhances care quality.

👨‍⚕️ Takeaway: The Briganti 2023 nomogram should be the go-to tool for predicting LNI in prostate cancer patients with negative PSMA PET-CT! 📈

🔗 Read the full study here: https://t.co/VrfJ25sjFX

#ProstateCancer #Urology #PSMAPET #LymphNodeDissection #Nomogram

[Miguel García Sanz @m_garciasanz]

🚨 #LeonEsp acogerá en 2027 la reunión de los grupos de Litiasis y Endourología y de Laparoscopia y Robótica de @InfoAeu

Os esperamos en nuestra ciudad, que aunará innovación y actualidad en una ciudad destacada por su patrimonio, cultura y gastronomía.

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer

https://t.co/GbMi9MisMI

This study investigated whether pelvic lymph node dissection (PLND) could be avoided in intermediate-risk #ProstateCancer patients with negative PSMA PET scans undergoing radical prostatectomy (RP). Of 371 patients identified, 333 underwent PLND while 38 did not. Kaplan-Meier analyses showed no significant difference in biochemical recurrence (BCR)-free survival at 36 months between those who had PLND (78.7%) and those who did not (76.7%).

The negative predictive value (NPV) of PSMA PET for detecting lymph node invasion (LNI) was 90.1%, suggesting that in patients with negative PSMA PET, PLND might be unnecessary. However, long-term oncologic outcomes were not assessed.

@rb_incesu
@MarkusGraefen
@Tilki_De

Ping @Silke_Gillessen @AOmlin @nataliagandur @bavilima

[Toni Choueiri, MD @DrChoueiri]

And NOW, TOP 5 PROSTATE CANCER trials of 2024!

1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile.
⛹🏼‍♂️A new player for doublets in mHSPC!

#ESMO24 Dr. Fred Saad @Silke_Gillessen @neerajaiims @umangtalking @DrRanaMcKay @JCO_ASCO

https://t.co/pdSS2DZJcX

[Lucas Regis @Dr_LRegis]

ROBOT THAT WATCHED SURGERY VIDEOS PERFORMS WITH SKILL OF HUMAN DOCTOR

That’s all folks, we are done 🤖
🆚
Well, now we have a copilot 👨‍✈️

Is there any role left for us in the future?

@LoebStacy @barret_e @JGomezRivas @DrJM_Gaya @MariaJRibal @dr_flozano

https://t.co/LwxSz3oV0P